{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/fa3ecf27-4910-41db-9127-4174e03e78df/39e1b406-de4c-440d-b471-ed18a1a3f56f?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"The T cell wars","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/61b9b47d42e8568ca498578e/61b9b4d59d2148001360f241.png?height=200","description":"<p><em>Nature Biotechnology</em>’s Irene Jarchum speaks with Michel Sadelain about off-the-shelf CAR-T cells, and discusses a recent paper from Maksim Mamonkin’s group describing a clever strategy to mitigate CAR-T cell rejection. The paper was published in <em>Nature Biotechnology</em> and can be read <a href=\"https://www.nature.com/articles/s41587-020-0601-5\" rel=\"noopener noreferrer\" target=\"_blank\">here</a>.</p>","author_name":"Nature Biotechnology"}